Three-Year Efficacy of Complex Insulin Regimens in Type 2 Diabetes
Open accessThe DOI matches its Crossref record; 25 of the 26 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Evidence supporting the addition of specific insulin regimens to oral therapy in patients with type 2 diabetes mellitus is limited. METHODS: In this 3-year open-label, multicenter trial, we evaluated 708 patients who had suboptimal glycated hemoglobin levels while taking metformin and sulfonylurea therapy. Patients were randomly assigned to receive biphasic insulin aspart twice daily, prandial insulin aspart three times daily, or basal insulin detemir once daily (twice if required). Sulfonylurea therapy was replaced by a second type of insulin if hyperglycemia became unacceptable during the first year of the study or subsequently if glycated hemoglobin levels were more than 6.5%. Outcome measures were glycated hemoglobin levels, the proportion of patients with a glycated hemoglobin level of 6.5% or less, the rate of hypoglycemia, and weight gain. RESULTS: Median glycated hemoglobin levels were similar for patients receiving biphasic (7.1%), prandial (6.8%), and basal (6.9%) insulin-based regimens (P=0.28). However, fewer patients had a level of 6.5% or less in the biphasic group (31.9%) than in the prandial group (44.7%, P=0.006) or in the basal group (43.2%, P=0.03), with 67.7%, 73.6%, and 81.6%, respectively, taking a second type of insulin (P=0.002). [corrected] Median rates of hypoglycemia per patient per year were lowest in the basal group (1.7), higher in the biphasic group (3.0), and highest in the prandial group (5.7) (P<0.001 for the overall comparison). The mean weight gain was higher in the prandial group than in either the biphasic group or the basal group. Other adverse event rates were similar in the three groups. CONCLUSIONS: Patients who added a basal or prandial insulin-based regimen to oral therapy had better glycated hemoglobin control than patients who added a biphasic insulin-based regimen. Fewer hypoglycemic episodes and less weight gain occurred in patients adding basal insulin. (Current Controlled Trials number, ISRCTN51125379.)
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Because many persons do not achieve adequate glycemic control with monotherapy or are at risk for early loss of efficacy with metformin or another monotherapy, combining antihyperglycemic agents is often appropriate.1060”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1060]
Citations
Cites
EuroQol: a new facility for the measurement of health-related quality of life
(1990) · Health Policy · doi:10.1016/0168-8510(90)90421-9 · Cited by 15,736
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751
Self-citationGlucose control and vascular complications in veterans with type 2 diabetes
Duckworth, W., Abraira, C., Moritz, T., Reda, D., Emanuele, N., Reaven, P. D., Zieve, F. J., Marks, J., Davis, S. N., Hayward, R., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808431 · Cited by 4,762
Nathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., & Zinman, B. (2009) · Diabetes Care · doi:10.2337/dc08-9025 · Cited by 3,834
Self-citationOhkubo, Y., Kishikawa, H., Araki, E., Miyata, T., Isami, S., Motoyoshi, S., Kojima, Y., Furuyoshi, N., & Shichiri, M. (1995) · Diabetes Research and Clinical Practice · doi:10.1016/0168-8227(95)01064-k · Cited by 3,079
Riddle (2003) · doi:10.2337/diacare.26.11.3080 · Cited by 1,479
Resistance to Insulin Therapy Among Patients and Providers
Peyrot, M., Rubin, R. R., Lauritzen, T., Skovlund, S. E., Snoek, F. J., Matthews, D. R., Landgraf, R., Kleinebreil, L., & Panel, O. B. O. T. I. D. A. (2005) · Diabetes Care · doi:10.2337/diacare.28.11.2673 · Cited by 783
Addition of Biphasic, Prandial, or Basal Insulin to Oral Therapy in Type 2 Diabetes
Holman, R. R., Thorne, K. I., Farmer, A. J., Davies, M. J., Keenan, J. F., Paul, S., & Levy, J. C. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa075392 · Cited by 710
Self-citationHermansen, K., Davies, M., Derezinski, T., Martinez Ravn, G., Clauson, P., Home, P., & on behalf of the Levemir Treat-to-Target Study Group (2006) · Diabetes Care · doi:10.2337/dc05-1365 · Cited by 627
Self-citation
Research works printed but not linked: 2
- Horvath K, 2007, Cochrane Database Syst Rev, 2, CD005613
- Siebenhofer A, 2006, Cochrane Database Syst Rev, 2, CD003287
Cited by
Items 401–500 of 666
Yamashiro, K., Ikeda, F., Fujitani, Y., Watada, H., Kawamori, R., & Hirose, T. (2010) · Journal of Diabetes Investigation · doi:10.1111/j.2040-1124.2010.00025.x · Cited by 6
Recomendaciones para el tratamiento farmacológico de la hiperglucemia en la diabetes tipo 2
Torre, E. L. M., Tejedor, J. L., Menéndez, S. A., Núñez-Cortés, J. M., Garcia, A. A., Puig‐Domingo, M., Soláns, J. R. G., Guisasola, F. Á., Alegría, J. G., Bravo, J. J. M., et al. (2011) · Medicina de Familia SEMERGEN · doi:10.1016/j.semerg.2010.11.002 · Cited by 7
Martínez, J. J. G. (2011) · Endocrinología y Nutrición (English Edition) · doi:10.1016/j.endoen.2011.09.002 · Cited by 8
Does Choice of Antidiabetes Therapy Influence Macrovascular Outcomes?
ZARICH, S. W. (2010) · Current Diabetes Reports · doi:10.1007/s11892-009-0083-9 · Cited by 6
A novel approach to optimise glycaemic control in insulin users
Bashan, E., Harper, R., Bi, Y., & Hodish, I. (2015) · BMJ Case Reports · doi:10.1136/bcr-2015-209356 · Cited by 6
Insulin therapy: Side effects and their management
Kashi, Z., Akha, O., Borzouei, S., & Bahar, A. (2013) · Clinical Excellence · Cited by 10
IDegAsp (insulin degludec + insulin aspart) for the management of type 2 diabetes: current status
Christiansen, J. S., Home, P., & Kumar, A. (2016) · Expert Review of Endocrinology & Metabolism · doi:10.1586/17446651.2016.1145541 · Cited by 6
Ghosh, S. K., Unnikrishnan, A. G., Saboo, B., Kesavadev, J., Aravind, S. R., Bajaj, S., Rajput, R., Seshadri, K., Verma, N., Gupta, A., et al. (2017) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2017.03.045 · Cited by 7
Intensive Insulin Therapy (Basal-Bolus)
Chico, A. I., & Corcoy, R. (2020) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000001152 · Cited by 6
Kroopnick, J. M., & Davis, S. N. (2022) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2022.2089021 · Cited by 6
“5% compared to the biphasic aspart group [37].”
BackgroundAre Analogue Insulins Superior to Human Insulin in Clinical Practice?
Freeman, J. S. (2010) · Current Diabetes Reports · doi:10.1007/s11892-010-0104-8 · Cited by 6
“A comparison between analogue regimens was recently reported by Holman et al. [ 37 ] with 3-year results from 708 patients with T2D receiving twice-daily biphasic insulin aspart (plus lunchtime insulin aspart if required), three-times daily insulin aspart (plus basal bedtime insulin detemir if required), or bedtime in…”
Backgroundde Miguel-Yanes, J. M., & Meigs, J. B. (2009) · The Oncologist · doi:10.1634/theoncologist.2009-0278 · Cited by 6
Kanatsuka, A., Kawai, K., Hirao, K., Yokoyama, H., & Kobayashi, M. (2012) · Diabetology International · doi:10.1007/s13340-012-0085-8 · Cited by 9
Wright, E. E., Shah, V. N., Miller, E. M., Thach, A., Javadi, P., Davies, S., & Sieradzan, R. (2025) · Diabetology · doi:10.3390/diabetology6020013 · Cited by 5
Préparations insuliniques au cours de la dernière décennie.
Monnier, L., & Colette, C. (2018) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(18)30034-8 · Cited by 5
Zainudin, A. M., Rasool, A. H. G., Yaacob, N. M., Muhamad, R., & Mohamed, W. M. I. W. (2024) · BMC Endocrine Disorders · doi:10.1186/s12902-024-01577-6 · Cited by 5
“Most of those on single insulin injection will require intensification within 3 years of insulin initiation [10].”
BackgroundUnger, J. (2011) · Diabetes Therapy · doi:10.1007/s13300-010-0014-4 · Cited by 5
Optimizing treatment strategies with insulin glargine in Type 2 diabetes
Owens, D. R. (2012) · Expert Review of Endocrinology & Metabolism · doi:10.1586/eem.12.29 · Cited by 5
Song, K., Kim, J. M., Noh, J.-H., Park, Y., Son, H.-S., Min, K. W., & Ko, K. S. (2013) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2013.37.2.117 · Cited by 5
Martínez, J. J. G. (2016) · Medicina Clínica · doi:10.1016/s0025-7753(17)30619-x · Cited by 8
Tabák, Á. G., Kempler, P., Guja, C., Eldor, R., Haluzík, M., Klupa, T., Παπάνας, Ν., Stoian, A. P., & Mankovsky, B. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01556-z · Cited by 5
“Early use of insulin may modify the disease course by restoring residual β -cell function [11] and by attenuating the risk of microvascular and long-term macrovascular complications [12, 13].”
BackgroundTibaldi, J. M. (2014) · The American Journal of the Medical Sciences · doi:10.1097/maj.0000000000000202 · Cited by 5
Newer insulins in type 2 diabetes
Gale, E. A. M. (2012) · BMJ · doi:10.1136/bmj.e4611 · Cited by 5
Mamza, J., Mehta, R. L., & IDRIS, I. R. (2014) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2014-000021 · Cited by 5
Current therapeutic agents and anesthetic considerations for diabetes mellitus
Kang, H. S. (2012) · Korean Journal of Anesthesiology · doi:10.4097/kjae.2012.63.3.195 · Cited by 5
“As initial therapy, unless the patient is markedly hyperglycemic and/or symptomatic, basal insulin is typically added [35].”
BackgroundHeron, L., Reaney, M. D., Hermanns, N., Abetz, L. N., & Gregg, L. C. (2013) · Diabetes Spectrum · doi:10.2337/diaspect.26.1.16 · Cited by 6
Different Insulin Initiation Regimens in Patients with Type 2 Diabetes - A Review Article
Mudassir, A. M., Thida, A. K., Meela, A., Eligar, V. S., Js, D., & Madelein, Y. (2018) · International Journal of Diabetes and Clinical Research · doi:10.23937/2377-3634/1410083 · Cited by 5
Migdal, A. L., Abrahamson, M. J., Peters, A. L., & Vint, N. (2018) · Annals of Medicine · doi:10.1080/07853890.2018.1493216 · Cited by 5
“basal alone or biphasic insulin mixtures [18].”
Pfohl, M., Pscherer, S., Fritsche, A., Anderten, H., Borck, A., Pegelow, K., Bramlage, P., & Seufert, J. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13768 · Cited by 5
“ever, the response is poor in a subset of individuals, with approximately 40% of those undergoing basal regimes failing to achieve HbA1c values ≤7% (53 mmol/mol) after 3 years.(3) Several predictors of response to basal insulin have been identified in T2DM patients: lower initial HbA1c,(4-6) shorter diabetes Received:…”
BackgroundSieber, J., Weinheimer, M., Kongable, G., Riddle, S., Chang, Y.-Y., & Flacke, F. (2019) · Journal of Diabetes Science and Technology · doi:10.1177/1932296819861586 · Cited by 5
Miyoshi, H., Baxter, M., Kimura, T., Hattori, M., Morimoto, Y., Marinkovich, D., Tamiwa, M., & Hirose, T. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01041-x · Cited by 6
Caballero, A. E., Nordstrom, B. L., Liao, B., Fan, L., Zhang, N., Fraeman, K. H., & Perez‐Nieves, M. (2021) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2021.108011 · Cited by 5
Thrasher, J. R., Bhargava, A., Rees, T. M., Wang, T., Guzmán, C. B., & Glass, L. C. (2014) · Endocrine Practice · doi:10.4158/ep14242.or · Cited by 5
Success of a sports-club led-community X-PERT Diabetes Education Programme
Morgan, A., Drew, D., Clifford, A., & Hull, K. (2016) · Sport in Society · doi:10.1080/17430437.2016.1173923 · Cited by 5
“Controlling blood glucose levels with insulin and sulfonylureas can also lead to serious health challenges attributable to associated weight gain and hypoglycaemia (Fonseca 2003; Amiel et al. 2008; Duckworth et al. 2009; Holman et al. 2009).”
BackgroundInzucchi, S. E., & Sherwin, R. S. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4377-1604-7.00562-5 · Cited by 6
Monnier, L., Colette, C., & Owens, D. R. (2018) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(18)30058-0 · Cited by 6
Shimoda, S., Okubo, M., Koga, K., Sekigami, T., Kawashima, J., Kukidome, D., Igata, M., Ishii, N., Shimakawa, A., Matsumura, T., et al. (2014) · Endocrine Journal · doi:10.1507/endocrj.ej14-0487 · Cited by 5
Galdo, J. A., Thurston, M. M., & Bourg, C. A. (2014) · Clinical Diabetes · doi:10.2337/diaclin.32.2.66 · Cited by 5
Ampudia‐Blasco, F. J., de la Cuadra-Grande, A., Bellido, V., Cuenca, A. M. C., Mezquita‐Raya, P., Carretero‐Gómez, J., Martínez, A.-M. H., Oyagüez, I., & Peralta, F. G. (2025) · Diabetes Technology & Therapeutics · doi:10.1177/15209156251363576 · Cited by 6
Insulin degludec 100 U/mL for treatment of spontaneous diabetes mellitus in dogs
Mott, J., Gal, A., Tardo, A. M., Berg, A. S., Claude, R., Hoelmer, A. M., Mui, M. L., Arjoonsingh, A., & Gilor, C. (2025) · Journal of Veterinary Internal Medicine · doi:10.1111/jvim.17303 · Cited by 7
Krentz, A. J., & Sinclair, A. J. (2011) · Drugs & Aging · doi:10.2165/11597820-000000000-00000 · Cited by 4
Shrivastava, A., Kesavadev, J., Mohan, V., Saboo, B., Shrestha, D., Maheshwari, A., Makkar, B. M., Modi, K. D., & Das, A. K. (2023) · Current Diabetes Reviews · doi:10.2174/1573399819666230109104300 · Cited by 7
“In another clinical study conducted on patients with uncontrolled T2DM who were taking SU and metformin and received either pre-mixed insulin, bolus insulin, or basal insulin analogue, the median HbA1c levels were similar among the groups [34].”
BackgroundResultCommon mistakes concerning diabetes management in daily clinical practice
Makrilakis, K., & Papachristoforou, E. (2024) · Primary care diabetes · doi:10.1016/j.pcd.2024.09.004 · Cited by 6
Management of Type 2 Diabetes Mellitus
Marks, J. B. (2011) · Springer eBooks · doi:10.1007/978-1-4614-1028-7_8 · Cited by 5
Continuous Subcutaneous Insulin Infusion for Managing Diabetes: Women's Health Implications
Hood, D. G. (2012) · Nursing for Women s Health · doi:10.1111/j.1751-486x.2012.01749.x · Cited by 4
Harashima, S., Tanaka, D., Yamane, S., Ogura, M., Fujita, Y., Murata, Y., Seike, M., Koizumi, T., Aono, M., Wang, Y., et al. (2012) · Hormone and Metabolic Research · doi:10.1055/s-0032-1323763 · Cited by 4
Nakashima, E., Kuribayashi, N., Ishida, K., Taketsuna, M., Takeuchi, M., & Imaoka, T. (2013) · Endocrine Journal · doi:10.1507/endocrj.ej12-0411 · Cited by 4
Otowa‐Suematsu, N., Sakaguchi, K., Nakamura, T., Hara, K., Kishi, M., Hashimoto, N., Yokota, K., Yoshino, H., Kuroki, Y., Nishiumi, T., et al. (2018) · Diabetes Therapy · doi:10.1007/s13300-018-0505-2 · Cited by 4
Mertes, B., Gödde, S., Piorkowski, M., Kramer, G., Müller, U., & Kuniß, N. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9041153 · Cited by 4
“Additionally, the risk of hypoglycaemia is lower compared with intensive insulin therapy with multiple injections of short-acting insulin [6].”
BackgroundInfluentialTakeshita, Y., Kita, Y., Tanaka, T., Goto, H., Nakano, Y., Teramura, C., Enyama, Y., Takamura, T., & the Establishment of Rationale for Antiaging Diabetic Medicine (ERA‐DM) Study Group (2022) · Journal of Diabetes Investigation · doi:10.1111/jdi.13749 · Cited by 3
McCrimmon, R. J., Home, P., CHENG, A. Y. Y., Giorgino, F., Fonseca, V. A., Souhami, E., Alvarez, A., Picard, P., & Rosenstock, J. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14825 · Cited by 3
For debate; pharmacological priorities in advanced type 2 diabetes
Hodish, I. (2019) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2019.107510 · Cited by 4
Takeshita, Y., Tanaka, T., Wakakuri, H., Kita, Y., Kanamori, T., & Takamura, T. (2020) · Journal of Diabetes Investigation · doi:10.1111/jdi.13471 · Cited by 3
Cardiovascular Disease and Glycemic Treatment
Bloomgarden, Z. T. (2010) · Diabetes Care · doi:10.2337/dc10-zb11 · Cited by 4
Gu, Y., Hou, X., Zhang, L., Pan, J., Cai, Q., Bao, Y., & Jia, W. (2011) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2011.0168 · Cited by 4
“The results of the 4T Study showed that the insulin requirements increased during the first 3 years of insulin introduction, and therefore daily cost may increase.(18) In the present study, although the daily cost of insulin in the BHI 30 monotherapy group decreased during the short follow-up period, the antidiabetes…”
ResultCan the current healthcare delivery model cope with advanced type 2 diabetes?
Hodish, I. (2015) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2015.01.005 · Cited by 4
“During the first few years after insulin initiation, dosage rises steadily although patients gain weight (about 5% of their body weight) mostly during the first 6 months (Holman et al., 2009).”
BackgroundInfluentialKrzymień, J., Koblik, T., & Nazar, M. (2010) · Polskie Archiwum Medycyny Wewnętrznej · doi:10.20452/pamw.991 · Cited by 4
Management of postprandial glucose: Recommended targets and treatment with biphasic insulin
Liebl, A. (2016) · Primary care diabetes · doi:10.1016/j.pcd.2016.06.002 · Cited by 5
Fournier, M., Germé, M., Theobald, K., Scholz, G. H., & Lehmacher, W. (2014) · PubMed Central · doi:10.3205/000199 · Cited by 5
Sendekie, A. K., Netere, A. K., & Belachew, E. A. (2022) · PLoS ONE · doi:10.1371/journal.pone.0275032 · Cited by 6
“At the initiation of therapy, initial regimens may help patients achieve blood glucose targets [7,9,10], but because of the progressive nature of the disease, finally both basal and prandial insulin will be required to maintain glycemic level within the target range [11].”
BackgroundUnger, J., Hinnen, D., Schreiner, B., & Parkin, C. (2012) · Journal of the American Academy of Nurse Practitioners · doi:10.1111/j.1745-7599.2012.00736.x · Cited by 4
“5 using basal insulin plus oral agents for more than 12 months (Holman et al., 2009).”
MethodInfluentialIto, H., Abe, M., Shinozaki, M., Oshikiri, K., Yamashita, H., Nakashima, M., Takaki, A., Yukawa, C., Furusho, M., Antoku, S., et al. (2013) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2013.0034 · Cited by 3
Hirsch, I. B., Schneider, D., King, A., Polonsky, W. H., Reid, T., Shubrook, J. H., Verderese, C. A., Wallace, J. I., & Riddle, M. C. (2014) · Postgraduate Medicine · doi:10.3810/pgm.2014.05.2763 · Cited by 3
Beale, E., Wa, L., & Chan, L. (2010) · Practical Diabetes · doi:10.1002/pdi.1506 · Cited by 3
Durán, S., Rivas, M. A. P., & Pérez, A. (2016) · Cited by 3
Management of Type 2 Diabetes – Methods for Addition of Prandial to Basal Insulin
Rodbard, H. W., & Karolicki, B. (2014) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2014.10.02.124 · Cited by 4
Postprandial plasma glucose effects of once-weekly albiglutide for the treatment of type 2 diabetes
Matthews, J. E., Reinhardt, R. R., & Carr, M. C. (2016) · Postgraduate Medicine · doi:10.1080/00325481.2016.1174565 · Cited by 3
“concluded in the Treating to Target in Type 2 diabetes trial.[9] Endogenous incretins, such as glucagon-like peptide 1”
BackgroundBerković, M. C., Petrovski, G., & Grulović, N. (2016) · Acta Diabetologica · doi:10.1007/s00592-016-0861-1 · Cited by 3
Pedone, E., Laurenzi, A., Allora, A., Bolla, A. M., & Caretto, A. (2020) · Exploration of Medicine · doi:10.37349/emed.2020.00021 · Cited by 3
Lechleitner, M., & Hoppichler, F. (2011) · Wiener Medizinische Wochenschrift · doi:10.1007/s10354-011-0889-3 · Cited by 11
Palliative management of type 2 diabetes mellitus in patients with advanced cancer
Weerasinghe, A., Good, P. D., Stokes, C., Chen, J., & Gurgenci, T. (2025) · Australian Journal of General Practice · doi:10.31128/ajgp-01-25-7522 · Cited by 3
Kakorin, S. V., Iskandaryan, R. A., & Mkrtumyan, A. M. (2016) · Diabetes Mellitus · doi:10.14341/dm2003422-27 · Cited by 3
La variabilité glycémique : un facteur de risque singulier à conjuguer au pluriel
Monnier, L., Colette, C., Bonnet, F., & Owens, D. R. (2021) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2021.11.003 · Cited by 3
The vexed question of hypoglycaemia and health economics
Home, P. (2014) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12266 · Cited by 3
“While a fair number of RCTs provide information on the incidence rate of hypoglycaemia on different insulin analogues [21], and the data is of relatively high quality, the population is usually selected to avoid those having other severe health problems, who as noted above have much of the highest incidence of severe…”
BackgroundEfficacy of Initial Basal-Supported Oral Therapy with Sitagliptin in Untreated Type 2 Diabetes
Yoshioka, K. (2013) · Diabetes Therapy · doi:10.1007/s13300-013-0043-x · Cited by 3
Beneficial and Detrimental Effects of Glycemic Control on Cardiovascular Disease in Type 2 Diabetes
Taub, P. R., Higginbotham, E., & Henry, R. R. (2013) · Current Cardiology Reports · doi:10.1007/s11886-012-0332-4 · Cited by 3
“An interventional trial utilizing biphasic insulin aspart, prandial insulin aspart, and basal insulin detemir to assess risks of hypoglycemia and other adverse effects in 708 participants found significantly increased hypoglycemic events in the basal insulin detemir cohort with respect to the other groups, but no diff…”
BackgroundRees, T. M., Curtis, B. H., Gaskins, K. A., Sierra‐Johnson, J., Jiang, H. H., Liu, R., & Holcombe, J. H. (2013) · Endocrine Practice · doi:10.4158/ep13301.or · Cited by 3
Vora, J. P., Punekar, Y. S., & Keech, M. L. (2011) · The British Journal of Diabetes · doi:10.1177/1474651411425802 · Cited by 3
the PRELANTI investigators, Tentolouris, N., Kyriazopoulou, V. E., Makrigiannis, D., & Baroutsou, B. (2013) · Diabetology & Metabolic Syndrome · doi:10.1186/1758-5996-5-43 · Cited by 3
Suzuki, T., Takahashi, K., Fujiwara, D., Shii, M., Takekawa, S., & Matsuoka, T. (2015) · Diabetology International · doi:10.1007/s13340-015-0239-6 · Cited by 4
Development of a New Tool to Assess Bolus Calculation and Carbohydrate Estimation
Ehrmann, D., Hermanns, N., Reimer, A., Weißmann, J., Haak, T., & Kulzer, B. (2016) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2015.0292 · Cited by 3
Conclusion : Comment équilibrer les buts et besoins thérapeutiques des soignants et des soignés ?
Monnier, L., & Colette, C. (2016) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(16)30032-3 · Cited by 3
Stachura, M. E., Rosenkoetter, M. M., Dias, J. K., Wood, E. A., & Brown, D. C. (2015) · International Journal of Health Sciences (IJHS) · doi:10.15640/ijhs.v3n1a1 · Cited by 3
Wade, M. T., & Rindone, J. P. (2011) · American Journal of Therapeutics · doi:10.1097/mjt.0b013e31820159aa · Cited by 3
“In these 2 trials, there was no statistical difference in the rate of hypoglycemia between groups; however, another large RCT involving 708 patients with T2DM demonstrated more hypoglycemic events with postprandial treatment (with short-acting insulin) versus patients on basal insulin.(27) These data do not support tr…”
ResultCohen, O., & Valentine, W. J. (2016) · Journal of Diabetes Science and Technology · doi:10.1177/1932296816667747 · Cited by 3
Do glycoalbumin levels preferentially reflect changes in postprandial glucose excursions?
Paul, S. K., & Holman, R. R. (2017) · Diabetic Medicine · doi:10.1111/dme.13376 · Cited by 4
“In the present study, we evaluated whether glycated albumin is more closely related to postprandial glycaemia than HbA1c, and whether it better reflects the insulin-induced changes in postprandial glucose excursions seen in the Treating-to-Target-in-Type 2 Diabetes (4-T) trial [27,28].”
BackgroundSelf-citationDiabetes mellitus and cardiovascular diseases
Pelikánová, T. (2011) · Cor et Vasa · doi:10.33678/cor.2011.054 · Cited by 3
Инсулинотерапия сахарного диабета второго типа
Gendeleka, G. F., & Gendeleka, A. N. (2020) · INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine) · doi:10.22141/2224-0721.16.1.2020.199130 · Cited by 4
Hirose, T., Odawara, M., Matsuhisa, M., Koshida, R., Senda, M., Tanaka, Y., & Terauchi, Y. (2020) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2020.108647 · Cited by 3
“[1] Holman RR, Farmer AJ, Davies MJ, Levy JC, Darbyshire JL, Keenan JF, et al.”
BackgroundStructure and properties of insulin
Gupta, A. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-820234-0.00004-4 · Cited by 5
Diabetes mellitus type 2 in the elderly
Rymkiewicz, E., Rękas-Wójcik, A., Milaniuk, S., Mosiewicz, B., & Dzida, G. J. (2015) · Polish Journal of Public Health · doi:10.1515/pjph-2015-0021 · Cited by 6
“Among available agents, insulin analogues are preferred to human insulin [10].”
BackgroundNishioka, Y., Hayashino, Y., Kurosawa, K., Takano, K., Matsunaga, S., Okamura, S., Tsujii, S., Ishii, H., & Diabetes Distress and Care Registry at Tenri Study Group (2025) · Diabetes Therapy · doi:10.1007/s13300-025-01755-2 · Cited by 2
“Hypoglycemia and weight gain are also problematic [37].”
Bertuol, V. C., Iorra, F. D. Q., Vieceli, T., Tonolli, N. T., Zappelini, R. D. S., van der Sand, L. F., Leitão, C. B., & Rados, D. R. V. (2025) · Diabetologia · doi:10.1007/s00125-025-06633-x · Cited by 3
Intensifying Treatment of Type 2 Diabetes Mellitus: Adding Insulin
Peters, K. R. (2011) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.31.12.54s · Cited by 4
“who added a biphasic insulin–based regimen.(42) Addition of basal insulin detemir also resulted in fewer hypo-glycemic episodes and less weight gain than the alternative regimens.”
BackgroundInsulin biobetters and biosimilars in clinical practice
Home, P. (2023) · The Journal of the Royal College of Physicians of Edinburgh · doi:10.1177/14782715231173770 · Cited by 5
Takahara, M., Shiraiwa, T., Katakami, N., Matsuoka, T., & Shimomura, I. (2014) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2014.0075 · Cited by 2
Insulin, other hypoglycemic drugs, and glucagon
Page, R. C. (2010) · Side effects of drugs annual · doi:10.1016/s0378-6080(10)32042-3 · Cited by 2
Koladi, M. A. (2014) · INDONESIAN JOURNAL OF PHARMACY · doi:10.14499/indonesianjpharm25iss3pp164 · Cited by 2
“The insulin analogs have similar potency as per dose by dose in comparison with conventional insulin, therefore, it is a common practice to use biphasic insulin twice/ thrice daily or biphasic human insulin twice a day with rapid acting human insulin before lunch (Holman et al., 2009).”
BackgroundInsulin degludec – The impact of a new basal insulin on care in type 2 diabetes
Khunti, K., Cos, X., & Rutten, G. E. H. M. (2013) · Primary care diabetes · doi:10.1016/j.pcd.2013.09.003 · Cited by 2
“[5] R.”
Background
Metadata
- Authors
- Holman, R. R., Farmer, A. J., Davies, M. J., Levy, J. C., Darbyshire, J. L., Keenan, J. F., & Paul, S. K.
- Affiliations
- University of Oxford (GB)
- University of Leicester (GB)
- Oxford Centre for Diabetes, Endocrinology and Metabolism (GB)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2009-10-29
- Volume
- 361
- Issue
- 18
- Pages
- 1736-1747
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2057595002
- Cited by
- 667
- References
- 26
- Citations by year
- 2026: 7 · 2025: 11 · 2024: 10 · 2023: 12 · 2022: 18 · 2021: 22 · 2020: 21 · 2019: 27 · 2018: 33 · 2017: 45 · 2016: 46 · 2015: 49 · 2014: 68 · 2013: 60 · 2012: 78
- FWCI
- 57.60
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- CINECA IRIS Institutial research information system (University of Pisa) (submittedVersion)
- Figshare (submittedVersion, cc-by)
- Leicester Research Archive (University of Leicester) (submittedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- type 2 diabetes, insulin therapy, biphasic insulin aspart, insulin detemir, basal insulin, HbA1c, glycemic control, hypoglycemia, weight gain, metformin, sulfonylureas
- MeSH terms
- Administration, Oral, Diabetes Mellitus, Type 2, Drug Administration Schedule, Drug Therapy, Combination, Glycated Hemoglobin, Humans, Hypoglycemia, Hypoglycemic Agents, Insulin, Metformin, Middle Aged, Sulfonylurea Compounds, Weight Gain
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.